Blog

FSD Pharma Adds David Urban to Board of Directors

TORONTO – November 14, 2018 – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of David Urban to the Company’s Board of Directors.
Mr. Urban is an accomplished business and government relations executive. He advises companies ranging in size from start-ups to the Fortune 100 on interaction with government in order to maximize stakeholder and shareholder value. In the field of politics, Mr. Urban has achieved success serving as an advisor to campaigns at the highest levels, including the President of the United States, the United States Senate and United States House of Representatives. In addition to his role as a government consultant and political advisor, Mr. Urban is a frequent contributor to CNN as a political commentator.

“It is an honor to welcome David Urban to the FSD Pharma Board of Directors. David has been a good friend and a personal advisor to us on policy relating to our industry in Washington, DC,” said Dr. Raza Bokhari, interim CEO and Co-Chairman of the Board. “His experience influencing public policy debates and as a bi-partisan government relations leader at the highest level will powerfully amplify FSD Pharma’s message regarding the compelling role that synthetic cannabinoids can play in effectively treating neurological disorders and finding a better solution to counter the opioid epidemic.”

“Our vision for FSD Pharma to become a global leader in medicinal cannabis is beginning to solidify. David’s legislative acumen will be of vital importance as we embark on a quest to affect the conversation on this very important topic in the US capitol,” said Anthony Durkacz Co-chairman & Co-Founder.

“David’s joining the Board as an independent Director is an important milestone for the Company and we welcome his expertise in advancing education and awareness about the potential contribution that cannabinoids can have in addressing the opioid epidemic,” added Zeeshan Saeed, President and Co-Founder.

“I’m pleased to be joining the FSD Pharma Board of Directors,” said Mr. Urban. “As the United States Congress and current Administration look at innovative ways to address the national crisis of opioid abuse, dependence, and overdose, I believe it’s important to work on a bi-partisan basis to expand awareness of research and development of synthetic cannabinoid pharmaceuticals as a viable option to this crisis.”

Mr. Urban joins the Board of Directors bringing important high-level experience and expertise in public policy, legislative and political arenas. Continue Reading

FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint

TORONTO – November 13, 2018 – FSD Pharma Inc. (“FSD Pharma” or the
“Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the
license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations. As of November 7, 2018, FV Pharma also received license amendments approving all of the remaining 25,000 square feet currently built out for additional grow and operations. The Company continues to move aggressively to achieve its next significant development of a further production footprint of 220,000 square feet. Thomas Fairfull, President, CEO and Founder of FV Pharma stated “The migration of the Company’s license, with the ability to sell under subsection 11(5) of the Cannabis Regulations, along with the recent addition of grow and operation areas to its existing license, brings the Company to the verge of readiness for a pre-sale inspection and obtaining of a full sales license from Health Canada.” Continue Reading

FSD Pharma Announces Positive ISA Report for “Steady Stomach” CBD Combination

TORONTO – November 6, 2018 – FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”) received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its “Steady Stomach” product.

The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive.

Under the terms of FSD’s strategic agreement with SciCann, FSD holds exclusive manufacturing and distribution rights for the “Steady Stomach” product in Canada.

Dr. Zohar Koren, Co-founder and CEO of SciCann stated, “This patent application covers the “Steady Stomach” product, for which we have recently launched the company’s first clinical study with Irritable Bowel Syndrome (IBS) patients. The preliminary affirmation we received from the ISA regarding the novelty of this unique combination therapy is an important milestone, which allows us to file national phase applications in the US, Canada and the rest of the world in order to achieve comprehensive IP protection for the product. We believe that our strategy of developing novel and proprietary synergistic combination cannabinoid therapies is the right approach to bring new and IP protected products to the cannabinoid based pharmaceutical space.”

Dr. Raza Bokhari, CEO of FSD Pharma stated, “This positive ISA report for CBD combination therapy is welcome news for FSD Pharma. We expect SciCann’s Steady Stomach product, currently in the phase I/II clinical development stage, to have a positive impact in the lives of IBS patients. FSD’s exclusive distribution rights for the product in Canada is in line with our company’s continuing efforts in research and development of novel and proprietary, cannabinoid-based treatments.” Continue Reading

FSD Pharma Announces Launch of IBS Clinical Study

TORONTO, Oct. 31, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics (“SciCann”). The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone. Continue Reading

FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-chairman and Zeeshan Saeed as President

TORONTO – October 29, 2018 – The Board of Directors of FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce the appointment of Dr. Raza Bokhari as interim CEO and Co-Chairman of the Board of Directors, replacing Thomas Fairfull.

Dr. Bokhari brings a wealth of knowledge in global business and healthcare services. He currently serves as the Chairman & CEO of PCL, a global diagnostic provider of addiction screening and opioid prescription medication monitoring, including designer drugs and synthetic cannabinoids. He is also the managing partner of RBx Capital, LP and Recipient of Philadelphia Business Journal’s “40 under 40” award. Physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies. He has a vast knowledge base of developing creative concepts, implementing programs and forming strategic alliances. Dr. Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University, Fox School of Business & Management.

Thomas Fairfull will retain his role as President and Chief Executive Officer of FV Pharma Inc., the Company’s wholly-owned subsidiary and licensed producer under the Cannabis Act. “With the arrival of Dr. Raza Bokhari, FSD’s global vision has begun to take shape and I am pleased to relinquish my role as CEO and Chairman of the Board of FSD to allow the Company to reach the next level, while at the same time allowing me to focus on building the largest hydroponic indoor-grow facility in the world and obtaining our sales license from Health Canada. It has been an honour to lead the talented team of executives and board members of FSD Pharma and I now pass on the reigns to Dr. Raza to take the company further into the medicinal cannabis space and to help finalize our acquisition of Therapix Biosciences Ltd. over the coming few weeks and other important initiatives in the coming months.” Continue Reading

FSD Pharma announces issuance of cannabis license under Excise Act

TORONTO, Oct. 25, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the Company’s application for a cannabis license under the Excise Tax Act has been conditionally approved by the Canada Revenue Agency (the “CRA”) and is effective as of October 17, 2018. The issuance of a cannabis license by the CRA is a requirement to sell cannabis and is a prerequisite to obtaining a sales license under the Cannabis Act.

Zeeshan Saeed, EVP, Director and Co-Founder of FSD Pharma stated, “The granting of this cannabis license by the CRA brings the Company one step closer to selling to the marketplace as we approach the granting of our sales license from Health Canada. In the meantime, we are continuing to deliver on our business plan and expanding our indoor grow facility in Ontario where an additional 220,000 square feet is currently under development.” Continue Reading

FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a NASDAQ Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments, to Create Medical Cannabis Industry Innovator

• Transaction combines two highly complementary businesses; the significant production and distribution of medical and recreational products by FSD Pharma, and the premium and differentiated medical and pharmaceutical brands by Therapix Biosciences;
• Brings together highly competent scientific and business leadership teams to execute upon a shared vision to deliver proprietary cannabinoid platform technologies to both professional and retail markets globally;
• Transaction strategic part of FSD Pharma’s interest to pursue access to international capital markets to attract high-quality, high-profile financial and strategic investors to participate in accelerating company growth plans and establishing a strong position in cannabinoid research space;
• Transaction focuses on Therapix proprietary IP and related technology and assets pertaining to all clinical stage pharmaceutical assets applications;
• Therapix Biosciences shareholders to receive $48 million USD of FSD Pharma stock;
• The Transaction is subject to the shareholder approval of both parties and further subject to additional pre-conditions required to be met prior to closing the Transaction no later than three months following the execution of a definitive agreement.

TORONTO – October 22, 2018 – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the signing of a binding letter of intent (the “LOI”) to acquire Therapix Biosciences Ltd. (“Therapix Biosciences” or “Therapix”) (NASDAQ: TRPX) effective October 22, 2018. The Transaction (the “Transaction”) combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments.

Therapix Biosciences shareholders will receive $48 million (USD) of FSD stock upon closing of the Transaction. The Transaction is structured at a fixed price of $48M USD ($62.4M CAD), representing approximately 130 million class B subordinate shares of FSD Pharma and nearly 10% of the Company today. The final number of class B subordinated shares and percentage ownership of the Company will fluctuate based on the 20 day average of the FSD Pharma stock closing price on the date the Transaction is finalized. The Transaction is arms’ length and no finders fees have been paid. It is anticipated that the common shares of the Company will continue to be listed on the Canadian Securities Exchange (CSE) and the Frankfurt Stock Exchange (FRA), and the Company intends to apply to list on NASDAQ, subject to regulatory approvals.

The terms of the LOI will be superseded by a definitive agreement, which FSD Pharma and Therapix intend to execute within 30 days. Continue Reading

FSD Pharma Featured on CTV Toronto

TORONTO, Oct. 17, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) is pleased to provide shareholders and interested parties with a link to the CTV Toronto program segment featuring interviews with executives and employees at the Company’s facility in Cobourg. In the segment, CEO and President Thomas Fairfull, Director Anthony Durkacz, and EVP and Director Zeeshan Saeed discuss job creation and the Company.

Interested shareholders and parties please visit: https://toronto.ctvnews.ca/video?clipId=1515888


Continue Reading

FSD Pharma and SciCann Therapeutics to Attend the CannX International Medical Cannabis Convention in Tel Aviv Israel

Toronto – October 14, 2018 – FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that its Head of Scientific Advisory Board, Dr. Zohar Koren, will attend the 3rd International Medical Cannabis Conference, (“CannX”) in Tel Aviv, Israel from October 14 to 16, 2018.

The CannX convention is a central annual meeting point of global leaders in all areas related to medical cannabis and cannabinoid medicine. The convention will feature the latest scientific developments in this rapidly evolving field, including cultivation, extraction and manufacturing cutting-edge technologies and clinical research breakthroughs. The convention will also showcase Key Opinion Leaders that are physicians and researchers including Professor Rafael Mechoulam, the Israeli scientist who was the first to discover the human endocannabinoid system. Continue Reading

FSD Pharma Congratulates High Tide Inc. for Closing Oversubscribed Private Placement and Announces $2 Million Lead Order

TORONTO, Oct. 10, 2018 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: OK9) (“FSD Pharma” or the “Company”) would like to congratulate High Tide Inc. (“High Tide”) on closing the second tranche of its brokered private placement (the “Offering”), for gross proceeds of approximately $18.3 million. The Offering, which was initially a $10 million financing, was upsized by over 83% due to strong demand from over 135 participating investors.

In line with its strategic direction, FSD Pharma has placed a lead order of $2 million in the Offering, for 1,449,276 special warrants of High Tide. This is the second time that the Company has provided a lead order in funding High Tide. FSD Pharma’s strategic investments and partnerships across the burgeoning Canadian cannabis industry continue to pave the way for the Company to achieve milestones in Canada and internationally. FSD Pharma will remain a strong support to High Tide as both companies continue to grow, and will continue to work collaboratively with High Tide as a supplier of cannabis products and accessories across Canada.

“In addition to High Tide currently being in various stages of securing dozens of retail locations for Cannabis sales in Alberta, British Columbia and Saskatchewan, with the change in recreational cannabis distribution policy by the new Ontario provincial government, we believe it offers a number of new exciting retail opportunities in Canada’s biggest province and we see further value in our partner High Tide,” stated Zeeshan Saeed, EVP and Director of FSD Pharma.

For more information on FSD Pharma: http://fsdpharma.com

About FSD Pharma

FSD Pharma owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR), which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

About High Tide

High Tide is a privately-held, Alberta-based, retail-focused cannabis corporation. It is among the most vertically-integrated companies in the Canadian cannabis market, with portfolio subsidiaries including RGR Canada Inc., Smoker’s Corner Ltd., Famous Brandz Inc., Canna Cabana Inc. and the majority of KushBar Inc. High Tide’s strategy as a parent company is to extend and strengthen its retail-focused integrated value chain, while providing a complete customer experience and maximizing shareholder value.

For more information about High Tide Inc., visit www.hightideinc.ca

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.